Contraception Care for Transmasculine Individuals on Testosterone Therapy
Abstract
Contraception and fertility-associated advisement is needed for any individual with a uterus who is engaging in sexual activity with reproductive potential. As greater awareness spreads regarding the health care needs of transgender, nonbinary, and gender-nonconforming individuals, the research on evidence-based care for these populations lags behind. Many clinicians may not be well versed in the best practices to support the sexual and reproductive well-being of individuals who are taking gender-affirming hormone therapy. This article reviews the use of contraception for individuals who are on testosterone gender-affirming hormone therapy. Each contraceptive method is individually considered for the risks and benefits that are unique to this population.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.